Call for Innovators: Roadshow Recruitment for the 3rd Health Industry Investment & Financing Leaders Summit

The outbreak of the COVID-19 pandemic has imposed new tests on the capital markets. Amidst the turbulence in financial markets, the dual impact of cooling capital and the pandemic has placed numerous industries in existential crisis. The fundraising landscape has become unprecedentedly severe, with limited partners (LPs) exercising greater caution in their commitments and fundraising cycles lengthening, while the financing needs of startup projects have become more urgent.

2020 is set to be another peak year for investment, mergers and acquisitions (M&A), and innovative R&D in China’s pharmaceutical industry. Healthcare has become the most immediate market demand, bucking the trend to emerge as the sector of greatest interest to VC/PE firms. Against the backdrop of weakening global economic recovery momentum, large-scale M&A activities in the global medical technology industry have been frequent, while equity investment returns in the healthcare sector have remained consistently robust. The introduction of a series of new market regulations—including the launch of the STAR Market, the implementation of the registration-based IPO system on the ChiNext Board, and accelerated IPO review processes—has made the future of China’s healthcare venture capital and private equity industry highly promising.

“The Analysis Report on Investment and Financing in China’s Healthcare Sector for the First Half of 2020” points out that in the first half of 2020, the proportion of financing deals for domestic healthcare companies accounted for 16% of all industries, reaching a record high. In terms of IPO performance, healthcare companies raised a total of RMB 41.5 billion through IPOs across all markets in the first half of the year, with RMB 17.8 billion raised on the A-share market, RMB 14.4 billion on the Hong Kong stock exchange, and RMB 9.3 billion on the U.S. stock market.

The establishment of the STAR Market has attracted numerous innovative healthcare companies to go public, with 11 medical enterprises listing on the board in the first half of the year. Recently, Qiu Linglong, Director of the Shenzhen Stock Exchange’s Zhejiang Base, stated that “the ChiNext Board will allow unprofitable health companies to list within a year.” This policy is expected to trigger a new wave of IPOs and attract more innovative healthcare firms to choose the A-share market as their listing venue.

In terms of financing scale and IPO size, an increasing number of Chinese healthcare companies are securing substantial capital investments, underscoring investor confidence in China’s healthcare sector.

In the fourth quarter of 2020, as social production and daily life generally returned to normal, investment and financing activities across various industries in China gradually picked up. According to the ranking of hot investment and financing sectors in the "National Investment and Financing Big Data Report for Q3 2020" released by Qichacha, medical health, manufacturing, enterprise services, hardware, and lifestyle services ranked among the top five. Notably, the number of financing events in the medical health sector increased by 39% year-on-year. Evidently, under the impact of the COVID-19 pandemic "black swan" event, institutional investors have shown a significant upward trend in their attention to the medical health sector.

Against this backdrop, for any company to keep pace in the current surge of industry momentum, it must not only solidify its R&D foundation but also secure support from diverse resources across the sector.

To this end, the Health Industry Investment and Financing Leaders Summit, jointly hosted by the Health Client of People’s Daily, People’s Daily Health Times, and BOC International Holdings Limited, with VCBeat as the chief media supporter, will be held in Beijing on November 1. The summit aims to streamline investment and financing channels, feature exclusive high-end roadshow sessions, jointly identify high-quality achievements in the biopharmaceutical field, facilitate the rapid translation and implementation of relevant scientific research outcomes, and boost the development of the biopharmaceutical industry.

Are you still worried about choosing the right financing channels for your enterprise?

Do you have multiple R&D pipelines running in parallel and urgently need financing opportunities?

Are you encountering bottlenecks in R&D and seeking expert evaluations and recommendations for your project?

We welcome projects in the fields of novel biologics, biosimilars, cell therapy, CRO services, medical devices, AI-driven biopharmaceuticals, and smart healthcare. Applications are also invited from projects at all stages (start-up, growth, or maturity). Projects that pass the review process will receive:

· Public roadshow opportunities at the official media industry summit

· Face-to-face networking opportunities with leading investment banks

· Professional guidance from scientists and industry experts

· Macro-level oversight by the management of the two stock exchanges

· Opportunities for connecting upstream and downstream industry resources

Event Schedule

▼Roadshow Registration▼

Scan the QR code below to fill in your information.

The Organizing Committee will contact you!

Registration Deadline: 2020.10.23

Contact: Guo Zhongxiao 13261860505